Format
Sort by
Items per page

Send to

Choose Destination

Best matches for atrial fibrillation AND cerebrovascular accident AND ischemic stroke AND thromboembolism:

Search results

Items: 1 to 20 of 802

1.

Oral anticoagulant persistence in patients with non-valvular atrial fibrillation: A cohort study using primary care data in Germany.

Collings SL, Lefèvre C, Johnson ME, Evans D, Hack G, Stynes G, Maguire A.

PLoS One. 2017 Oct 10;12(10):e0185642. doi: 10.1371/journal.pone.0185642. eCollection 2017.

2.

Comparison of the CHADS<sub>2</sub>, CHA<sub>2</sub>DS<sub>2</sub>-VASc and R<sub>2</sub>CHADS<sub>2</sub> Scores in Japanese Patients with Non-valvular Paroxysmal Atrial Fibrillation Not Receiving Anticoagulation Therapy.

Yoshizawa R, Komatsu T, Kunugita F, Ozawa M, Ohwada S, Satoh Y, Morino Y, Nakamura M.

Intern Med. 2017 Sep 25. doi: 10.2169/internalmedicine.8914-17. [Epub ahead of print]

3.

Meta-Analysis of Safety and Efficacy of Uninterrupted Non-Vitamin K Antagonist Oral Anticoagulants Versus Vitamin K Antagonists for Catheter Ablation of Atrial Fibrillation.

Elgendy AY, Mahtta D, Barakat AF, Abuzaid A, Mahmoud A, Mentias A, Mahmoud AN, Elgendy IY.

Am J Cardiol. 2017 Aug 8. pii: S0002-9149(17)31302-4. doi: 10.1016/j.amjcard.2017.07.096. [Epub ahead of print]

PMID:
28882334
4.

Left atrial appendage closure for prevention of death, stroke, and bleeding in patients with nonvalvular atrial fibrillation.

Gloekler S, Saw J, Koskinas KC, Kleinecke C, Jung W, Nietlispach F, Meier B.

Int J Cardiol. 2017 Aug 26. pii: S0167-5273(17)33620-3. doi: 10.1016/j.ijcard.2017.08.049. [Epub ahead of print]

PMID:
28882323
5.

Risk of stroke in congestive heart failure with and without atrial fibrillation.

Kang SH, Kim J, Park JJ, Oh IY, Yoon CH, Kim HJ, Kim K, Choi DJ.

Int J Cardiol. 2017 Dec 1;248:182-187. doi: 10.1016/j.ijcard.2017.07.056. Epub 2017 Jul 20.

PMID:
28826798
6.

Warfarin Use in Patients With Atrial Fibrillation Undergoing Hemodialysis: A Nationwide Population-Based Study.

Yoon CY, Noh J, Jhee JH, Chang TI, Kang EW, Kee YK, Kim H, Park S, Yun HR, Jung SY, Oh HJ, Park JT, Han SH, Kang SW, Kim C, Yoo TH.

Stroke. 2017 Sep;48(9):2472-2479. doi: 10.1161/STROKEAHA.117.017114. Epub 2017 Aug 11.

PMID:
28801476
7.

Left atrial appendage closure using AMPLATZER™ devices: A large, multicenter, Italian registry.

Berti S, Santoro G, Brscic E, Montorfano M, Vignali L, Danna P, Tondo C, D'Amico G, Stabile A, Saccà S, Patti G, Rapacciuolo A, Poli A, Golino P, Magnavacchi P, De Caterina A, Meucci F, Pezzulich B, Rezzaghi M, Stolcova M, Tarantini G.

Int J Cardiol. 2017 Dec 1;248:103-107. doi: 10.1016/j.ijcard.2017.07.052. Epub 2017 Jul 16.

PMID:
28797952
9.

Effects of Smoking on Ischemic Stroke, Intracranial Hemorrhage, and Coronary Artery Events in Japanese Patients With Non-Valvular Atrial Fibrillation.

Suzuki S, Otsuka T, Sagara K, Semba H, Kano H, Matsuno S, Takai H, Kato Y, Uejima T, Oikawa Y, Nagashima K, Kirigaya H, Yajima J, Kunihara T, Sawada H, Aizawa T, Yamashita T.

Int Heart J. 2017 Aug 3;58(4):506-515. doi: 10.1536/ihj.16-228. Epub 2017 Jul 13.

10.

Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.

Almutairi AR, Zhou L, Gellad WF, Lee JK, Slack MK, Martin JR, Lo-Ciganic WH.

Clin Ther. 2017 Jul;39(7):1456-1478.e36. doi: 10.1016/j.clinthera.2017.05.358. Epub 2017 Jun 28. Review.

PMID:
28668628
11.

Abnormal P-Wave Axis and Ischemic Stroke: The ARIC Study (Atherosclerosis Risk In Communities).

Maheshwari A, Norby FL, Soliman EZ, Koene RJ, Rooney MR, O'Neal WT, Alonso A, Chen LY.

Stroke. 2017 Aug;48(8):2060-2065. doi: 10.1161/STROKEAHA.117.017226. Epub 2017 Jun 16.

PMID:
28626057
12.

Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II).

Steinberg BA, Shrader P, Thomas L, Ansell J, Fonarow GC, Gersh BJ, Hylek E, Kowey PR, Mahaffey KW, O'Brien EC, Singer DE, Peterson ED, Piccini JP; Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Investigators and Patients.

Am Heart J. 2017 Jul;189:40-47. doi: 10.1016/j.ahj.2017.03.024. Epub 2017 Apr 4.

13.

Rationale and design of the Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA) trial.

Lopes RD, Alings M, Connolly SJ, Beresh H, Granger CB, Mazuecos JB, Boriani G, Nielsen JC, Conen D, Hohnloser SH, Mairesse GH, Mabo P, Camm AJ, Healey JS.

Am Heart J. 2017 Jul;189:137-145. doi: 10.1016/j.ahj.2017.04.008. Epub 2017 Apr 24.

PMID:
28625370
14.

Incidence and functional outcome of atrial fibrillation and non-atrial fibrillation- related cardioembolic stroke in Joinville, Brazil: a population-based study.

Amaral CHD, Amaral AR, Nagel V, Venancio V, Garcia AC, Magalhaes PS, Longo AL, Moro CH, Reis FI, D'Avila A, Cabral NL.

Arq Neuropsiquiatr. 2017 May;75(5):288-294. doi: 10.1590/0004-282X20170039.

15.

Impact of renal function on ischemic stroke and major bleeding rates in nonvalvular atrial fibrillation patients treated with warfarin or rivaroxaban: a retrospective cohort study using real-world evidence.

Weir MR, Berger JS, Ashton V, Laliberté F, Brown K, Lefebvre P, Schein J.

Curr Med Res Opin. 2017 Oct;33(10):1891-1900. doi: 10.1080/03007995.2017.1339674. Epub 2017 Jul 11.

PMID:
28590785
16.

Effect of Addition of a Statin to Warfarin on Thromboembolic Events in Japanese Patients With Nonvalvular Atrial Fibrillation and Diabetes Mellitus.

Kumagai N, Nusser JA, Inoue H, Okumura K, Yamashita T, Kubo T, Kitaoka H, Origasa H, Atarashi H; J-RHYTHM Registry Investigators.

Am J Cardiol. 2017 Jul 15;120(2):230-235. doi: 10.1016/j.amjcard.2017.04.011. Epub 2017 Apr 27.

PMID:
28532776
17.

Analytical Management of Patients Undergoing Oral Anticoagulant Therapy Could Have a Strong Impact on Clinical Outcomes: A Follow-up Study.

De Iuliis V, Ursi S, Vitullo G, Griffo I, Marino A, Caruso M, Cipollone F, Capodifoglio S, Breda V, Toniato E, Pennelli A, Conti P, Martinotti S.

Cardiol Ther. 2017 May 19. doi: 10.1007/s40119-017-0090-x. [Epub ahead of print]

PMID:
28526929
18.

Rivaroxaban - Metabolism, Pharmacologic Properties and Drug Interactions.

Kvasnicka T, Malikova I, Zenahlikova Z, Kettnerova K, Brzezkova R, Zima T, Ulrych J, Briza J, Netuka I, Kvasnicka J.

Curr Drug Metab. 2017;18(7):636-642. doi: 10.2174/1389200218666170518165443.

PMID:
28524005
19.

The Population-Based Long-Term Impact of Anticoagulant and Antiplatelet Therapies in Low-Risk Patients With Atrial Fibrillation.

Golive A, May HT, Bair TL, Jacobs V, Crandall BG, Cutler MJ, Day JD, Mallender C, Osborn JS, Stevens SM, Weiss JP, Woller SC, Bunch TJ.

Am J Cardiol. 2017 Jul 1;120(1):75-82. doi: 10.1016/j.amjcard.2017.03.256. Epub 2017 Apr 12.

PMID:
28483209
20.

Risk of arterial and venous thromboembolism in patients with atrial fibrillation or flutter: A nationwide population-based cohort study.

Sundbøll J, Hováth-Puhó E, Adelborg K, Ording A, Schmidt M, Bøtker HE, Sørensen HT.

Int J Cardiol. 2017 Aug 15;241:182-187. doi: 10.1016/j.ijcard.2017.04.081. Epub 2017 Apr 26.

PMID:
28473169

Supplemental Content

Loading ...
Support Center